生物
自噬
MHC I级
免疫系统
主要组织相容性复合体
抗原呈递
癌症研究
CD8型
溶酶体
T细胞
免疫学
免疫监视
细胞凋亡
生物化学
酶
作者
Keisuke Yamamoto,Anthony Venida,Rushika M. Perera,Alec C. Kimmelman
出处
期刊:Autophagy
[Taylor & Francis]
日期:2020-05-27
卷期号:16 (8): 1524-1525
被引量:82
标识
DOI:10.1080/15548627.2020.1769973
摘要
Major histocompatibility complex class I (MHC-I) is a key molecule in anti-tumor adaptive immunity. MHC-I is essential for endogenous antigen presentation by cancer cells and subsequent recognition and clearance by CD8+ T cells. Defects in MHC-I expression occur frequently in several cancers, leading to impaired antigen presentation, immune evasion and/or resistance to immune checkpoint blockade (ICB) therapy. Pancreatic ductal adenocarcinoma (PDAC), a deadly malignancy with dismal patient prognosis, is resistant to ICB and shows frequent downregulation of MHC-I independent of genetic mutations abrogating MHC-I expression. Previously, we showed that PDAC cells exhibit elevated levels of autophagy and lysosomal biogenesis, which together support the survival and growth of PDAC tumors via both cell-autonomous and non-cell-autonomous mechanisms. In our recent study, we have identified NBR1-mediated selective macroautophagy/autophagy of MHC-I as a novel mechanism that facilitates immune evasion by PDAC cells. Importantly, autophagy or lysosome inhibition restores MHC-I expression, leading to enhanced anti-tumor T cell immunity and improved response to ICB in transplanted tumor models in syngeneic host mice. Our results highlight a previously unknown function of autophagy and the lysosome in regulation of immunogenicity in PDAC, and provide a novel therapeutic strategy for targeting this deadly disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI